BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27555433)

  • 1. Dysfibrinogenemia-associated novel heterozygous mutation, Shanghai (FGA c.169_180+2 del), leads to N-terminal truncation of fibrinogen Aα chain and impairs fibrin polymerization.
    Zhou J; Ding Q; Wu W; Ouyang Q; Xie Y; Wu X; Lu Y; Dai J; Liang Q; Wang H; Wang X; Hu Y
    J Clin Pathol; 2017 Feb; 70(2):145-153. PubMed ID: 27555433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
    Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
    Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His.
    Luo M; Deng D; Xiang L; Cheng P; Liao L; Deng X; Yan J; Lin F
    Medicine (Baltimore); 2016 Sep; 95(39):e4864. PubMed ID: 27684817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital hypodysfibrinogenemia associated with a novel deletion of three residues (γAla289_Asp291del) in fibrinogen.
    Zhu L; Zhao M; Wang M; Lou Z; Chen X; Pan L; Yu D; Xia W; Wang H; Zhou B; Gao S
    J Thromb Thrombolysis; 2018 Aug; 46(2):211-218. PubMed ID: 29748775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
    Terasawa F; Kani S; Hongo M; Okumura N
    Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of molecular structure and fibrin polymerization between two Bβ-chain N-terminal region fibrinogen variants, Bβp.G45C and Bβp.R74C.
    Kaido T; Yoda M; Kamijo T; Taira C; Higuchi Y; Okumura N
    Int J Hematol; 2020 Sep; 112(3):331-340. PubMed ID: 32562089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal fibrinogen with an Aα 16Arg → Cys substitution is associated with multiple cerebral infarctions.
    Luo M; Wei A; Xiang L; Yan J; Liao L; Deng X; Deng D; Cheng P; Lin F
    J Thromb Thrombolysis; 2018 Oct; 46(3):409-419. PubMed ID: 29869737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical characterization of fibrinogen Caracas I with an Aalpha-chain truncation at Aalpha-466 Ser: identification of the mutation and biophysical characterization of properties of clots from plasma and purified fibrinogen.
    Marchi R; Meyer M; de Bosch N; Soria J; Arocha-Piñango CL; Weisel JW
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):285-93. PubMed ID: 15166913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Nový Jicín and Praha II: cases of hereditary Aalpha 16 Arg-->Cys and Aalpha 16 Arg-->His dysfibrinogenemia.
    Kotlín R; Chytilová M; Suttnar J; Riedel T; Salaj P; Blatný J; Santrůcek J; Klener P; Dyr JE
    Thromb Res; 2007; 121(1):75-84. PubMed ID: 17408725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA).
    Marchi R; Carvajal Z; Meyer M; Soria J; Ruiz-Saez A; Arocha-Piñango CL; Weisel JW
    Thromb Res; 2006; 118(5):637-50. PubMed ID: 16406498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
    Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens.
    Kotlín R; Blažek B; Suttnar J; Malý M; Kvasnička J; Dyr JE
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):640-8. PubMed ID: 20829681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
    Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
    Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygous Bβ-chain C-terminal 12 amino acid elongation variant, BβX462W (Kyoto VI), showed dysfibrinogenemia.
    Okumura N; Terasawa F; Takezawa Y; Hirota-Kawadobora M; Inaba T; Fujita N; Saito M; Sugano M; Honda T
    Blood Coagul Fibrinolysis; 2012 Jan; 23(1):87-90. PubMed ID: 22001526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
    Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Functional analysis for dysfibrinogenemias, Toyama and Adachi, which have a mutation of Aalpha16Arg-->His (CGT-->CAT) with aberrant fibrinopeptide A release].
    Soya K; Takezawa Y; Terasawa F; Okumura N
    Rinsho Byori; 2012 Jun; 60(6):499-505. PubMed ID: 22880226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
    Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
    Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation (deletion of Aalpha-Asn 80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot.
    Marchi RC; Meyer MH; de Bosch NB; Arocha-Piñango CL; Weisel JW
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):559-67. PubMed ID: 15389122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.